L-CCG-ll

Discontinued Product

L-CCG-ll (Cat. No. 0330) has been withdrawn from sale for commercial reasons.
Description: Weak NMDA agonist
Alternative Names: (2S,3R,4R)-CCG
Chemical Name: (2S,1'R,2'R)-2-(Carboxycyclopropyl)glycine
Datasheet
Citations
Reviews
Literature (5)

Biological Activity for L-CCG-ll

Conformationally restricted glutamic acid analogue.

Licensing Information

Sold with the exclusive permission of Suntory Ltd.

Technical Data for L-CCG-ll

M. Wt 159.14
Storage Store at RT
CAS Number 117857-94-0

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for L-CCG-ll

Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service

References for L-CCG-ll

References are publications that support the biological activity of the product.

Shinozaki et al (1989) Potent NMDA-like actions and potentiation of glutamate responses by conformational variants of a glutamate analogue in the rat spinal cord. Br.J.Pharmacol. 98 1213 PMID: 2692753

Testa et al (1997) Selective metabotropic receptor agonists distinguish non-ionotropic glutamate binding sites. Brain Res. 773 15 PMID: 9409700

View Related Products by Target

View Related Products by Product Action

View all NMDA Receptor Agonists

Keywords: L-CCG-ll, L-CCG-ll supplier, (2S,3R,4R)-CCG, NMDA, Receptors, 0330, Tocris Bioscience

Citations for L-CCG-ll

Citations are publications that use Tocris products.

Currently there are no citations for L-CCG-ll.

Reviews for L-CCG-ll

There are currently no reviews for this product. Be the first to review L-CCG-ll and earn rewards!

Have you used L-CCG-ll?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.